CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced that it has assembled world-class Scientific and Clinical Advisory Boards.
“Cardiovascular disease is the leading cause of death in both men and women and accounts for one-third of deaths worldwide1,2,” said Daniel Bloomfield, M.D., chief executive officer at Cardurion Pharmaceuticals. “The insight and expertise of our scientific and clinical advisory board will be critical as we advance our pipeline of novel treatments to reduce the burden of this public health issue. We are honored and extremely fortunate to welcome such distinguished visionaries and clinicians to the team.”
Cardurion Pharmaceuticals is pleased to share the members of its Scientific and Clinical Advisory Boards.
Cardurion Pharmaceuticals Scientific Advisory Board
- Eric Olson, Ph.D., scientific advisory board chairman, Cardurion Pharmaceuticals; professor and chairman, UT Southwestern Medical Center
- Douglas Mann, M.D., chief of cardiology, Washington University School of Medicine
- David Kass, M.D., professor of medicine and cardiology, John Hopkins University School of Medicine
"Cardurion is targeting key and well validated pathways to enhance heart function,” said Dr. Eric Olson, scientific advisory board chairman, Cardurion Pharmaceuticals. “Cardurion has a tremendous team with deep expertise in developing pioneering therapies, and I look forward to working alongside these leaders to advance treatments for heart failure and other cardiovascular disorders.”
Cardurion Pharmaceuticals Clinical Advisory Board
- James Udelson, M.D., clinical advisory board chairman, Cardurion Pharmaceuticals; chief of cardiology, Tufts Medical Center and professor of medicine and radiology, Tufts University School of Medicine
- Eugene Braunwald, M.D., distinguished Hersey professor of medicine, Harvard Medical School; founding chairman, Thrombolysis in Myocardial Infraction Study Group
- John McMurray M.D., professor of medical cardiology and deputy director of the Institute of Cardiovascular and Medical Sciences at the University of Glasgow, UK
- Scott Solomon, M.D., the Edward D. Frohlich distinguished chair, professor of medicine, Harvard Medical School; senior physician, Brigham and Women’s Hospital
“There remains a critical need for innovation to address the burden of several major cardiovascular diseases, including heart failure,” said Dr. Eugene Braunwald. “I am deeply impressed by Cardurion’s team and focus and believe this new company is well poised to make a real difference to patients.”
For additional information on Cardurion Pharmaceuticals’ Scientific and Clinical Advisory Boards, please visit the company’s website: http://www.cardurion.com.
About Cardurion Pharmaceuticals
Cardurion is a biotechnology company with both clinical and preclinical programs focused on the development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases. Led by two physician-scientists with extensive experience in cardiovascular science, medicine and drug development, Cardurion’s unique programs and strongly collaborative environment enable the company to deliver promising treatments that target major unmet needs. Cardurion has facilities in Cambridge, Massachusetts and Shonan, Japan. For more information, please visit the company’s website at http://www.cardurion.com.
Cardurion Pharmaceuticals’ Forward Looking Statements
This press release contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Any statements contained herein that do not describe historical facts, are forward-looking statements that are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcomes, timing and performance to differ materially from those expressed or implied by such statements. These factors, risks and uncertainties include, but are not limited to: the costs and uncertainties associated with our research efforts and other discovery activities; the inherent uncertainties associated with the conduct, timing and results of preclinical and clinical studies of our product candidates; and the adequacy of our capital resources and availability of additional funding. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release, and we undertake no obligation to update or revise any of such statements to reflect events or circumstances occurring after this press release. We caution readers not to place undue reliance on the forward-looking statements contained in this press release.
The safety and efficacy of the agent discussed herein are under investigation and have not been established. There is no guarantee that the agent will receive regulatory approval and become commercially available for the uses being investigated. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.